386 related articles for article (PubMed ID: 32474642)
21. Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes.
Mackay TM; Gleeson EM; Wellner UF; Williamsson C; Busch OR; Groot Koerkamp B; Keck T; van Santvoort HC; Tingstedt B; Pitt HA; Besselink MG;
Surgery; 2021 Feb; 169(2):396-402. PubMed ID: 32868111
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy of pancreatic cancer.
Willett CG; Czito BG; Bendell JC
Cancer J; 2007; 13(3):185-91. PubMed ID: 17620768
[TBL] [Abstract][Full Text] [Related]
23. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy in operable pancreatic cancer.
Wente MN; Büchler P; Friess H; Büchler MW
Swiss Surg; 2002; 8(2):74-80. PubMed ID: 12013694
[TBL] [Abstract][Full Text] [Related]
25. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.
Youngwirth LM; Nussbaum DP; Thomas S; Adam MA; Blazer DG; Roman SA; Sosa JA
J Surg Oncol; 2017 Aug; 116(2):127-132. PubMed ID: 28407261
[TBL] [Abstract][Full Text] [Related]
26. Minimally invasive surgery for pancreatic cancer.
Miyasaka Y; Ohtsuka T; Nakamura M
Surg Today; 2021 Feb; 51(2):194-203. PubMed ID: 32857251
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic cancer surgery: the state of the art.
Kim SC; Kim YH; Park KM; Lee YJ
Curr Drug Targets; 2012 Jun; 13(6):764-71. PubMed ID: 22458522
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?
Lim KH; Chung E; Khan A; Cao D; Linehan D; Ben-Josef E; Wang-Gillam A
Oncologist; 2012; 17(2):192-200. PubMed ID: 22250057
[TBL] [Abstract][Full Text] [Related]
29. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
30. The role of neoadjuvant therapy in pancreatic cancer: a review.
Russo S; Ammori J; Eads J; Dorth J
Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
[TBL] [Abstract][Full Text] [Related]
31. Resection and radiochemotherapy of pancreatic cancer--the future?
Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.
Grossberg AJ; Chu LC; Deig CR; Fishman EK; Hwang WL; Maitra A; Marks DL; Mehta A; Nabavizadeh N; Simeone DM; Weekes CD; Thomas CR
CA Cancer J Clin; 2020 Sep; 70(5):375-403. PubMed ID: 32683683
[TBL] [Abstract][Full Text] [Related]
33. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
35. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial.
Mackay TM; Smits FJ; Latenstein AEJ; Bogte A; Bonsing BA; Bos H; Bosscha K; Brosens LAA; Hol L; Busch ORC; Creemers GJ; Curvers WL; den Dulk M; van Dieren S; van Driel LMJW; Festen S; van Geenen EJM; van der Geest LG; de Groot DJA; de Groot JWB; Haj Mohammad N; Haberkorn BCM; Haver JT; van der Harst E; Hemmink GJM; de Hingh IH; Hoge C; Homs MYV; van Huijgevoort NC; Jacobs MAJM; Kerver ED; Liem MSL; Los M; Lubbinge H; Luelmo SAC; de Meijer VE; Mekenkamp L; Molenaar IQ; van Oijen MGH; Patijn GA; Quispel R; van Rijssen LB; Römkens TEH; van Santvoort HC; Schreinemakers JMJ; Schut H; Seerden T; Stommel MWJ; Ten Tije AJ; Venneman NG; Verdonk RC; Verheij J; van Vilsteren FGI; de Vos-Geelen J; Vulink A; Wientjes C; Wit F; Wessels FJ; Zonderhuis B; van Werkhoven CH; van Hooft JE; van Eijck CHJ; Wilmink JW; van Laarhoven HWM; Besselink MG;
Trials; 2020 Apr; 21(1):334. PubMed ID: 32299515
[TBL] [Abstract][Full Text] [Related]
36. Multimodality management of localized pancreatic cancer.
Wayne JD; Wolff RA; Pisters PW; Evans DB
Cancer J; 2001; 7 Suppl 1():S35-46. PubMed ID: 11504284
[TBL] [Abstract][Full Text] [Related]
37. Surgery for pancreatic cancer: current controversies and challenges.
Karunakaran M; Barreto SG
Future Oncol; 2021 Dec; 17(36):5135-5162. PubMed ID: 34747183
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Han S; Choi SH; Choi DW; Heo JS; Han IW; Park DJ; Ryu Y
Minerva Chir; 2020 Feb; 75(1):15-24. PubMed ID: 31115240
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Chen J; Li D; Killary AM; Sen S; Amos CI; Evans DB; Abbruzzese JL; Frazier ML
Ann Surg Oncol; 2009 Feb; 16(2):431-9. PubMed ID: 19020940
[TBL] [Abstract][Full Text] [Related]
40. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
